Biosergen
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Fogdevreten 2, Solna, Stockholm, 17165, ...Phone Number
+45 20802470Website
www.biosergen.netRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biosergen
Biosergen is a biotech company focused on developing innovative antifungal drugs, particularly targeting immunocompromised patients such as those with AIDS, cancer, and transplant recipients. Their lead product, BSG005, is designed to provide superior safety and potency compared to existing treatments for invasive fungal infections. The company aims to revolutionize care for patients suffering from life-threatening fungal diseases through cutting-edge research and development. With a commitment to improving the quality of life for these patients, Biosergen is advancing its groundbreaking solutions globally.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biosergen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Biosergen recently announced quarterly report
Funding: Get notified immidiatlly once Biosergen has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Biosergen
Click to see if Biosergen had a recent Job posting/layoffs
Check if Biosergen has recently received funding, and reach out quickly before it becomes old news!
Check out if Biosergen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Biosergen launches new products
Biosergen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Biosergen
Find 3 more new buyers
Company Profile Activity
Activity Insights
Biosergen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biosergen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biosergen.
Biosergen Tech Stack
A closer look at the technologies used by Biosergen
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Project
Clinical Systems, Product Management
Promotion
Executive Move
Lateral Move
Executive Move
Biosergen News & Media
Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3
The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 5, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, resolved on a directed issue of 734,963 shares to such underwriters in the warrantBiosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3
The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 3, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, decided on a directed share issue of 6,348,670 shares (the "Directed Issue") to aBiosergen AB receives approximately SEK 44.9 million through warrants of series TO3
Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total number of outstanding warrants of series TO3, for subscription of 91,701,328 shares at an exercise price of SEK 0.49 per share. Biosergen will receiveBiosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections
November 26, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, is pleased to announce that the first two patients in the second cohort of its ongoing proof-of-concept clinical trial for BSG005 has successfully begun treatment with BSG005. The patients are suffering from a severe infection caused by Aspergillus and Mucor Mycosis respectively. These two patients represent challenging cases where current antifungal
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biosergen
Sign Up For FreeTo access detailed company insights
Biosergen is a biotech company focused on developing innovative antifungal drugs, particularly targeting immunocompromised patients such as those with AIDS, cancer, and transplant recipients. Their lead product, BSG005, is designed to provide superior safety and potency compared to existing treatments for invasive fungal infections. The company aim... Read More
